Literature DB >> 8878318

Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder.

S H Kennedy1, S P Kutcher, E Ralevski, G M Brown.   

Abstract

Nine bipolar patients (2 men and 7 women) and 12 healthy control subjects completed overnight sampling for serum melatonin (MT) and urinary 6-sulphatoxymelatonin (aMT6s). The patients were investigated during manic, depressed, and/or euthymic states. Although serum MT levels did not differ significantly across the bipolar groups, in all cases serum MT levels were significantly lower than in control subjects. Differences in MT levels were also present between bipolar patients who were in a depressed phase and control subjects. There were no statistically significant differences in urinary aMT6s levels among the patients and control subjects, although in all cases nocturnal aMT6s levels were significantly higher than daytime levels. This study provides tentative evidence for decreased serum MT as a trait but not a state marker in bipolar affective disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878318     DOI: 10.1016/0165-1781(96)02910-1

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  21 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 2.  Melatonin, circadian rhythms, and the clock genes in bipolar disorder.

Authors:  Sara Dallaspezia; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

3.  [Bipolar disorder vulnerability: The vitamin D path].

Authors:  Manel Naifar; Manel Maalej Bouali; Wassim Guidara; Ahmed Slim Ellouze; Khalil Jmal; Sana Omri; Meriam Messedi; Lobna Zouari; Aida Elleuch; Mohamed Maalej; Khansa Chaabouni; Nada Charfi; Mouna Turki; Ben Thabet Jihène; Fatma Ayadi
Journal:  Can J Psychiatry       Date:  2019-08-21       Impact factor: 4.356

4.  Life events and social rhythms in bipolar spectrum disorders: an examination of social rhythm sensitivity.

Authors:  Elaine M Boland; Rachel E Bender; Lauren B Alloy; Bradley T Conner; Denise R Labelle; Lyn Y Abramson
Journal:  J Affect Disord       Date:  2012-02-29       Impact factor: 4.839

Review 5.  Circadian Rhythm Dysregulation in Bipolar Spectrum Disorders.

Authors:  Lauren B Alloy; Tommy H Ng; Madison K Titone; Elaine M Boland
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

Review 6.  Chronobiology of bipolar disorder: therapeutic implication.

Authors:  Sara Dallaspezia; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

7.  Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia.

Authors:  Hader A Mansour; Michael E Talkowski; Joel Wood; Kodavali V Chowdari; Lora McClain; Konasale Prasad; Debra Montrose; Andrea Fagiolini; Edward S Friedman; Michael H Allen; Charles L Bowden; Joseph Calabrese; Rif S El-Mallakh; Michael Escamilla; Stephen V Faraone; Mark D Fossey; Laszlo Gyulai; Jennifer M Loftis; Peter Hauser; Terence A Ketter; Lauren B Marangell; David J Miklowitz; Andrew A Nierenberg; Jayendra Patel; Gary S Sachs; Pamela Sklar; Jordan W Smoller; Nan Laird; Matcheri Keshavan; Michael E Thase; David Axelson; Boris Birmaher; David Lewis; Tim Monk; Ellen Frank; David J Kupfer; Bernie Devlin; Vishwajit L Nimgaonkar
Journal:  Bipolar Disord       Date:  2009-11       Impact factor: 6.744

Review 8.  Pharmacological Manipulation of the Circadian Clock: A Possible Approach to the Management of Bipolar Disorder.

Authors:  Alessandra Porcu; Robert Gonzalez; Michael J McCarthy
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 9.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

Review 10.  Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.

Authors:  Lindsay M Melhuish Beaupre; Gregory M Brown; Vanessa F Gonçalves; James L Kennedy
Journal:  Transl Psychiatry       Date:  2021-06-02       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.